Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tangential flow filtration for isolating exomeres and other nanoscale extracellular particles.

Nanoscale·2026
Same author

Generation of Cellular Biofactories for the Scalable Production of Surface-Engineered Extracellular Vesicles via CRISPR Genome Editing.

ACS biomaterials science & engineering·2026
Same author

Plasma signals of lung tumor promotion for molecular cancer prevention.

Cell·2026
Same author

NRSF regulation of OPRM1 through histone acetylation.

Clinical epigenetics·2026
Same author

Associations of 6600 SomaScan proteins with demographic, lifestyle, environmental and health characteristics in Chinese adults.

Scientific reports·2026
Same author

Endoplasmic reticulum stress induced autophagy alters cellular processing of cationic lipid delivered siRNAs.

Drug delivery and translational research·2026

Related Experiment Video

Updated: Jun 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Cancer-drug associations: a complex system.

Ertugrul Dalkic1, Xuewei Wang, Neil Wright

  • 1Center for Systems Biology, Michigan State University, East Lansing, Michigan, USA.

Plos One
|April 7, 2010
PubMed
Summary

Cancer drug networks reveal that death statistics influence drug approvals and sharing, but molecular data shows weak overlap. Breast cancer is uniquely linked in both FDA and clinical trial networks.

Area of Science:

  • Oncology
  • Network Science
  • Pharmacology

Background:

  • Network analysis of large-scale medical data reveals global relationships between drugs, targets, and diseases.
  • Smaller-scale network analysis offers detailed insights into individual members and interactions, complementing global topological descriptions.
  • Investigating factors, such as mortality statistics, that govern drug-cancer pairings is crucial.

Purpose of the Study:

  • To construct and analyze cancer networks based on drug approvals and clinical trials.
  • To determine the influence of global and local lethality (death rates) on drug-cancer relationships.
  • To compare drug-target based cancer networks with mutation-target based networks.

Main Methods:

  • Defined global and local lethality values to represent cancer-specific death rates.

Related Experiment Videos

Last Updated: Jun 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

  • Generated two cancer networks: one for Food and Drug Administration (FDA)-approved drugs and another for drugs in clinical trials.
  • Utilized correlation and linear regression to analyze the impact of lethality on drug approval and sharing.

    • Main Results:

    • Breast cancer showed significant connectivity in both FDA and clinical trial networks; lung cancer in the FDA network; ovarian cancer and lymphoma in the clinical trial network.
    • Global lethality correlated with drug approval and trial numbers, while local lethality influenced drug sharing.
    • A weak overlap was observed between mutation-target and drug-target based cancer networks.

    Conclusions:

    • Cancer-drug association networks are differentially connected, with breast cancer being a key node in both FDA and clinical trial networks.
    • Cancer-drug associations are moderately influenced by death statistics, impacting drug approvals, trials, and sharing.
    • Molecular information shows limited overlap with drug-target based networks, suggesting distinct drivers for cancer-drug relationships.